NEW YORK (

TheStreet

) --The 2012 BIO CEO & Investor Conference kicks off this morning here at the Waldorf-Astoria Hotel.

The two-day conference, put on by BIO, the biotech industry's main lobbying group, typically spotlights small-cap biotech companies that are often shut out of investor conferences run by large investment banks.

Biotech companies scheduled to present today include

Celsion Pharmaceuticals

(CLSN) - Get Report

,

Cyclacel Pharmaceuticals

(CYCC) - Get Report

,

Chelsea Therapeutics

(CHTP)

,

Navidea Biopharmaceuticals

(NAVB) - Get Report

,

Galena Biopharma

(GALE)

,

Titan Pharmaceuticals

(TTNP) - Get Report

and

Oxigene

(OXGN)

.

Today's agenda also includes panel discussions on cancer clinical trials, the "beta amyloid debate" in Alzheimer's disease drug research and biotech financing.

On Tuesday, biotech and drug presenters include

Delcath Systems

(DCTH)

,

Keryx Pharmaceuticals

(KERX) - Get Report

,

Oncothyreon

(ONTY)

,

Acorda Therapeutics

(ACOR) - Get Report

and

Idenix Pharmaceuticals

(IDIX)

.

Gilead Sciences'

(GILD) - Get Report

President John Milligan will also be featured in a "fireside chat."

To make it easier to follow the news, debate and conversations expected to flow from this years BIO CEO confab, feel free to check in periodically to this live blog that will aggregate all tweets using the #BIOCEO2012 hashtag.

--Written by Adam Feuerstein in New York.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.